Health Technology Assessment

104 Items

All Items

  • Budget impact analysis of extended half-life recombinant factor IX (rFIXFc) in the treatment of haemophilia B

    Andrea Aiello, Maria Elisa Mancuso, Alessio Colombo, Cristina Teruzzi, Patrizia Berto
    40-49
    DOI: https://doi.org/10.33393/grhta.2020.2113

  • The effects of disease cross-coverage by dupilumab on the costs sustained by the Italian National Health Service

    Claudio Jommi, Filippo Cipriani, Francesca Fanelli, Maria Paola Pedone, Walter Canonica
    33-39
    DOI: https://doi.org/10.33393/grhta.2020.2139

  • Evaluation of the use of Floseal®, a topical hemostatic agent, in cardiothoracic surgery

    Rossella Di Bidino, Luz Irene Urbina, Marco Oradei, Amerigo Cicchetti
    14-25
    DOI: https://doi.org/10.33393/grhta.2020.695

  • A cost-minimization analysis of a preventive testing strategy for relatives of patients with BRCA mutated ovarian cancer

    Eugenio Di Brino, Matteo Ruggeri, Stefania Boccia, Nicoletta Cerana, Domenica Lorusso, Dario Sacchini, Antonella Savarese, Liliana Varesco, Americo Cicchetti
    1-8
    DOI: https://doi.org/10.33393/grhta.2020.557
101-125 of 104